117238-61-6

Basic information

• Product Name: 3 5-DIBROMO-2-HYDROXY-4-METHOXYBENZALDE&
• Synonyms: 3 5-DIBROMO-2-HYDROXY-4-METHOXYBENZALDE&
• CAS NO: 117238-61-6
• Molecular Formula: C₈H₆Br₂O₃
• Molecular Weight: 309.94
• Product Categories: Aldehydes;C8;Carbonyl Compounds
• Mol File: 117238-61-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 97-101 °C(lit.)
• Boiling Point: 317.5°C at 760 mmHg
• Flash Point: 145.8°C
• Appearance: /
• Density: 1.988g/cm³
• Vapor Pressure: 0.000206mmHg at 25°C
• Refractive Index: 1.651
• CAS DataBase Reference: 3 5-DIBROMO-2-HYDROXY-4-METHOXYBENZALDE&(CAS DataBase Reference)
• NIST Chemistry Reference: 3 5-DIBROMO-2-HYDROXY-4-METHOXYBENZALDE&(117238-61-6)
• EPA Substance Registry System: 3 5-DIBROMO-2-HYDROXY-4-METHOXYBENZALDE&(117238-61-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 117238-61-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H6Br2O3/c1-13-8-5(9)2-4(3-11)7(12)6(8)10/h2-3,12H,1H3

Upstream product

• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 
• 67-56-1 methanol 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 6615-24-3 2-hydroxy-4-methoxy-5-nitrobenzaldehyde 
• 150-19-6 O-methylresorcine 
• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 10442-39-4 tetra-n-butylammonium cyanide 
• 214687-87-3 5,7-Dibromo-6-methoxy-1-oxa-spiro[2.5]octa-5,7-dien-4-one 
• 116096-91-4 3,5-dibromo-2,4-dihydroxy benzaldehyde 
• 77-78-1 dimethyl sulfate 
• 623-11-0 1-methyl-4-nitrosobenzene 

Downstream Products

• 343256-49-5 3,5-dibromo-2-(O-methoxymethylenoxy)-4-methoxybenzaldehyde 
• 35031-47-1 2-(benzyloxy)-3,5-dibromo-4-methoxybenzaldehyde 
• 945628-74-0 C₁₁H₁₀Br₂O₅ 
• 1421511-73-0 N'-(3,5-dibromo-2-hydroxy-4-methoxybenzylidene)biphenyl-4-carbohydrazide 
• 1421511-87-6 6-bromo-N'-(3,5-dibromo-2-hydroxy-4-methoxybenzylidene)-2-naphthohydrazide 
• 1011473-78-1 C₂₅H₂₀Br₆N₆O₆*ClH 

Relevant articles and documents

Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors

Receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR), are critically involved in the transduction of mitogenic signals across the plasma membrane and therefore in the regulation of cell growth and proliferation. Enhanced RTK activity is associated with proliferative diseases such as cancer, psoriasis and atherosclerosis, while decreased function may be associated for instance with diabetes. EGFR and PDGFR are selectively inhibited by analogues of the marine natural product aeroplysinin. The synthetic inhibitors display IC50 values in the low micromolar range and in contrast to the natural product show pronounced inhibitory activity in cultured cells in vivo. The mechanism of inhibition is likely based on a covalent modification of the target enzymes by reaction of epoxy ketone 8 with various nucleophiles. Copyright (C) 1998 Elsevier Science Ltd.

3-substituted coumarin derivative and application and GPR35 receptor agonist

The invention discloses a 3-substituted coumarin derivative and a pharmaceutically acceptable salt, a solvate, a hydrate or a crystal form. The compound of the invention generally exhibits high agonistic activity against human G protein-coupled receptor 35 (GPR35) and is specific agonists of the human GPR35 receptor. The compound provided by the invention is an active ligand of the novel GPR35 receptor, and the compound and the pharmaceutically acceptable salt, the solvate, the hydrate or the crystal form thereof generally exhibit higher activity and good selectivity to the human GPR35. The 3-substituted coumarin derivative is the specific agonist of the GPR35 receptor and can be used in the preparation of a medicament for treating, preventing and inhibiting a disease mediated by the GPR35receptor.

Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate

SIRT1 is an NAD+-dependent deacetylase, whose activators have potential therapeutic applications in age-related diseases. Here we report a new class of SIRT1 activators. The activation is dependent on the fluorophore labeled to the substrate. To elucidate the activation mechanism, we solved the crystal structure of SIRT3/ac-RHKKac-AMC complex. The structure revealed that the fluorophore blocked the H-bond formation and created a cavity between the substrate and the Rossmann fold. We built the SIRT1/ac-RHKK ac-AMC complex model based on the crystal structure. Km and Kd determinations demonstrated that the fluorophore decreased the peptide binding affinity. The binding modes of SIRT1 activators indicated that a portion of the activators interacts with the fluorophore through π-stacking, while the other portion inserts into the cavity or interacts with the Rossmann fold, thus increasing the substrate affinity. Our study provides new insights into the mechanism of SIRT1 activation and may aid the design of novel SIRT1 activators.

Antiangiogenic versus cytotoxic activity in analogues of aeroplysinin-1

A series of analogues of the potentially angiogenic inhibitor aeroplysinin-1 1 were synthesized and their in vitro antiangiogenic and cytotoxic activities evaluated. In the case of epoxy ketone 6 and azlactone 36 the relationship sprouting inhibition assay/cytotoxicity in BAE cells was enhanced by one order and two orders of magnitude, respectively, with respect to the reference. These results imply more specific antiangiogenic properties for the synthesized derivatives.